CLINICAL GUIDELINES Breast Imaging Guidelines Version 1.0 Effective January 1, 2021
eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies:This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight.
CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2020 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.
© 2020 eviCore healthcare. All rights reserved.
Breast Imaging Guidelines V1.0
Breast Imaging Guidelines Abbreviations for Breast Guidelines 3 BR-Preface1: General Considerations 5 BR-1: Breast Ultrasound 8 BR-2: MRI Breast 10 BR-3: Breast Reconstruction 12 BR-4: MRI Breast is NOT Indicated 13 BR-5: MRI Breast Indications 14 BR-6: Nipple Discharge/Galactorrhea 18 BR-7: Breast Pain (Mastodynia) 19 BR-8: Alternative Breast Imaging Approaches 20 BR-9: Suspected Breast Cancer in Males 21 BR-10: Evaluation in Pregnant or Lactating Women 22
______©2020 eviCore healthcare. All Rights Reserved. Page 2 of 26 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com 0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______Breast ©2020 BI GERD COPD HRCT LFTP DCIS MRA LCIS EMG MRV AVM PEM ECG CAD AAA - NCV FDG ACE CTA CTV PET PFT MRI IPF RADS BP PE CT
GI Imaging l Rights All eviCore healthcare.
Guidelines electromyogram pulmonary positron positron pulmonary nerve magnetic magnetic magnetic localized lobular idiopathic high gastrointestinal gastroesophageal fluorodeoxyglucose electrocardiogram ductal computed computed computed chronic computer blood Breast arteriovenous angiotensin abdominal Abbreviations
resolution
pressure conduction
carcinoma
Imaging
carcinoma obstructive - emission
emission
fibrous -
resonance resonance resonance
pulmonary aided
tomography tomography tomography aortic function embolus - converting
malformation
computed
Reporting
detection
tumor
aneurysm
in
velocity
tomography mammography in reflux
Reserved.
pulmonary
tests situ
situ venography imaging angiography fibrosis
venography angiography of enzyme
disease
the tomography for and
pleura
disease Database
Breast
System 8924 BRCA CBC FDA FNA DVT
EM Guidelines
deep Complete tumor fine Administration Food electromagnetic
needle
venous
and suppressor
Drug blood
aspiration www.eviCore.com
thrombosis
count Page
gene
3
of V1.0
26
Breast Imaging 0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______Breast ©2020 RODEO SVC SPN PPD
Imaging l Rights All eviCore healthcare.
Guidelines superior solitary Rotating purified
pulmonary protein
vena
Delivery
cava
derivative
of
nodule Reserved.
Excitation
of
tuberculin
Off - resonance
8924
MRI www.eviCore.com Page 4 of V1.0 26
Breast Imaging Breast Imaging Guidelines V1.0
BR-Preface1: General Considerations BR-Preface1.0: General Guidelines 6 BR-Preface1.1: BI-RADS™ Categories Chart 6 BR-Preface1.2: BI-RADS™ Breast Density Categories 7
______©2020 eviCore healthcare. All Rights Reserved. Page 5 of 26 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com 0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______BR- BR- Breast ©2020 Category 1: Negative Category 0: Incomplete Category Suggested Follow Interval – Finding Benign 3: Probably Category 2: BenignCategory Finding Current clinical evaluation is not required prior to screening studies. advanced imaging. A current clinical evaluation (within 60 days) is usually required prior to considering Preface1.1 .0 Preface1
Imaging l Rights All eviCore healthcare. A clinical evaluation should include the following:
Category established patientcan substitute a face for- Other meaningful contact (telephone call, electronic mail or messaging) by an mammogram and/orultrasound Appropriate laboratory studies and non- A relevant history and physical examination Guidelines - up Short : : :
BI General
- RADS
BI study be specified, e.g.study bespecified, ultrasound, additional mammogram 0classification Category additional imagingthat requires mammographic evidencemammographic of ma fat calcifications, e secretory multipl fibroadenomas, describewish a to calcified finding. Involuting, isThis also a negative mammogram, but the interpreter may are calcifications suspicious andnosymmetrical or masses, architectural disturbances, is nothingThere commentto on. breasts areThe MRIview, comparison Need additional imaging evaluation prior mammograms or for findings that should that findings be interval follow available becoming on light sheds that the would radiologist the is notIt expected to change over the follow beingprobability benign. of A placed in categoryfinding should havethis avery high vali as the to accrue data will These undergointuitive. modification as future likely more implants, etc.nodes, while concluding still that is nothere might wishinterpreter intramammary to describe lymph andappearances, may be labeled with The confidence. and mixed density all hamartomas) have characteristic lesions (such containing oilas cysts, lipomas, galactoc - Reserved. RADS™
Guidelines ™ dity of an approach,dity and of the interval required, the type of
Categories .
Categories .
- up. At At up. the time,present most approaches are
advanced imaging modaliti prefer establishprefer Data itsto stability. is
followed.
Description
Chart 8924 Chart
to
- present. face clinical evaluation
lignancy.
efficacy short of - up interval, but up interval, but www.eviCore.com es,such as Page - eles, 6 of V1.0 26
Breast Imaging Category D: ExtremelyCategory dense C: Category B: ScatteredCategory densit fibroglandular A: AlmostCategory entire fatty 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______BR- Breast ©2020 Be Taken Action Should Appropriate Malignancy –Proven 6: KnownCategory Biopsy Be Taken Action Should Appropriate of– Malignancy Suggestive Category Be ConsideredShould Abnormality 4: SuspiciousCategory Preface1.2
Imaging eviCore healthcare Rights . All
Category
5: Highly Highly 5: Heterogeneously dense Guidelines – Biopsy : :
BI
BI - - RADS™ RADS™ -
BI
malignant. Th should bebiopsied or surgically treated lesions haveThese ahigh being probability of cancer and decision onthe of ultimate action. course so cited that patientthe and her physician make can the aurge biopsy. possible, If the possibilities shouldrelevant be concern to sufficienthas radiologist The being malignant. of of breastmorphologies cancer but have a definite probability are lesions There dothat not have the characteristic - Reserved. RADS™ ese lesions have been biopsied andare known beto
Breast
Breast
Categories i
es Density
Density
Categories Description
8924 8924 Chart
Categories
. .
www.eviCore.com
Page 7 of V1.0 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 necessary Ultrasound US Axilla especially limited) Breast Routine biopsy any nipple scre State Specific Density Reporting and Imaging Mandate Laws usefulness. automated 3D nonspecific, Palpable BI
- Imaging eviCore healthcare Rights . All RADS
Equivocal U density Breast Bilateral For If months If A ultrasound abnormality not individuals should nodes Reconstruction
guided Additional order, ening
ltrasound repeat repeat
clinical ult
inversion) See CPT Radiologist MRI ultrasound to indicated
women
can rasound performance
™ breast . document Guidelines
3
mammography densit in be assessed
regardless
for
notification breast ® breast Breast from CH- Breast
Cat shoul be
imaging imaging equivocal 76642) off differentiating
or
breast
risk lesi with
scr
wit used 2.2: Axillary2.2: Lymphadenopathy ice 3 has
Occu
. masses
the y 1,2,3 should (CPT
d
ons eening h
biopsy ultrasound ultrasound notification (CPT Report a a
profile. can visit (CPT
be successful successful
clinically been
date and
is r to BR-1: ultrasound. FNA
emains
lt of of
should
® laws coded
or
be BI-R further is Findings: ®
as 76882)
breast
be ® age.
or
inconclusive
76641: (CPT for of uncertain.
identified not recommendation is repeated 76376 or
cysts
benign
othe evaluated ADS
vary, the
Reserved.
inappropriate. women BI-R
biopsy
suspicious follow CPT (ABUS); necessary be Ultrasound laws
® evaluate Breast
ultrasound lesion
initial r
19083) ™ 1 1 ™
billed unilateral, from It or clinical but ® ADS
(Cat is have
on can can 76882x 2. at up CPT
whose
or some commonly
imaging.
or
with sampling solid least there recent using ™
imaging
2).
2, abnormalities
includes lymph ® help prior been conflicting abnormalities can
3,
16
76377) 1,2,3 then as Ultrasound
mammography
6 complete also lesions for
only
repeat is CPT
identify stand- enhance (within months to
put
no After Breast nodes, imaging
for
if
requested contain breast
indication
the
®
histology in the Chest Imaging Guidelines evidence is 8924 8924 into
.
stable 19084. 1 at findings
2 2 alone
not
the imaging
OR
patients
after
12
found ultrasound years
(such effect preoperative
biopsy ultrasound
considered reverts mandates
last
months, CPT
findings
screening
and an is in is
to
on
on of by
60
as dense
conjunction
component. . benign
® who support 3 US
stability,
mammography breast
76642: mammogram, skin many to days)
(CPT
18 directed
at
routine when have for
medically axillary
6 breast
or change, months, and
states. states.
www.eviCore.com
ultrasound, mammogram. additional its
months
® unilateral,
with
the
76641 positive
an clinical with Page per
tissue breast
finding
Breast pain, and
8 or or
of V1.0
is in
24
26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______Breast ©2020
Imaging eviCore healthcare Rights . All i involving maging, Guidelines
which members
may
in
include
these Reserved. states, MRI
and/or
their
ultrasound. legislative 8924 8924
mandates
For
applicable
should www.eviCore.com requests
be Page followed. 9
of V1.0 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 pharmacokinetic analysis), when performed; bilateral CPT document MRI MRI the use of (CPT 77047) or preferred Magnetic most computer Magnetic resonance imaging, breast, without and with contrast material(s), including pharmacokinetic algorithm The The equivocal unnecessary integrity Magnetic resonance imaging, breast, without contrast material; bilateral (CPT pharmacokinetic computer Computer
Imaging eviCore healthcare Rights . All Additional HCPCS CPT Since The The with MRI interpretation. investigational,
® use use Breast guided ® individuals 77048
7704
B
® use use further
in of of
- 76377 -
reast Magnetic resonance imaging, breast, without contrast material; unilateral the Guidelines resonance in successful successful analysis - or aided detection (CAD real aided
gadolinium contrast.
aided asymptomatic,
gadolinium gadolinium
code can 6) 6)
breast of of some
uncertain.
procedures.
with CAD lesio H
maybe performed CAD
physician data
be CP detection should
for detection analysis, analysis), 9
C8937.
these
individuals
ns
of
software experimental, biopsy repeated CS the has for
imaging, MRI should lesion
5 contrast contrast
code lesion not
evaluation procedures. little
review B
The
average- (CAD (CPT with
(CAD)
BR-2: when
be reast automatically Reserved.
sampling
C8937 be
at influence use after breast, detection/characterization,
used
further least ® is is
billed real for
19085) data and/or
performed; is if there are clinical reasons or concerns regarding not required
of mas of risk
interpretation) included - -
in (CAD 6 6
time lesion detection, characterization and time HCPCS
MRI
breast
necessary physician physician without
if using
for conjunction
months on tectomy
patients. u histology
includes
lesion nproven.
lesion performs the including for
Breast CPT parenchyma.
with unilateral
code and sensitivity the a , ,
fter detection/characterization, per detection, review for ®
is
the
the evaluation 8924 8924 with 19086. is
with
C8937
3D benign computer the
an physician currently
MRI (CPT imaging
contrast (CPT
imaging,
MRI CPT
for evaluation specificityand
pharmacokinetic B
(CAD ® characterization interpretation) and
reast ® directed ® 77049 of
77049,
77048 considered algorithm component. request.
breast material(s), nonspecific,
CPT including
CPT ) of ) is
breast ®
CPT implant may www.eviCore.com
® 76376 preferred parenchyma. of
77049 analysis Page
®
is MRI
computer be analysis,
77048 including and biopsy or 10 ®
B and
reast in of
V1.0 of
or
26
to
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Practice Breast ©2020 Although mammogram malignancies, increase malignant identified lesions”
Imaging eviCore healthcare Rights . All Notes . 6,7 with MRI by Guidelines
varies
MRI
younger and Breast it
carries
from Breast
ultrasound.
has
3% age a a
in
significant
superior to . .
only The
Reserved. 20%
Incidental
0.7% percentage
depending
sensitivity
false
of
those lesions
positive of
in on
with inci
identifying
are the 8924 8924 risk dental
“inconclusive
patient seen
when
lesions
on new
population. compared
15%
unknown
that mammographic
of
MRI
turn www.eviCore.com
to Cancer Page B
out reast
to 11
is
be of V1.0 and 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 advanced There CTA can can
Imaging eviCore healthcare Rights . All Deep Inferior Epigastric Perforators (DIEP) flap. For example, CTA 74174) be
or
is
performed MRA
currently Guidelines
imaging or MRA Abdomen MRA or and/or
of
the
BR-3: insufficient
for
for
body
breast TRAM A bdomen
part
Breast reconstruction Reserved.
flaps evidence- from and
or which
/or
Pelvis Pelvis
other
Reconstruction P based
elvis the
flaps (CPT preoperative
free data (CPT
performed ® tissue
8924 8924 74185 and
to 8 ®
74175CPT or support transfer planning. on a /or
the
CPT flap vascular
need 2,3 ®
is ®. www.eviCore.com 72191CPT or 72198) for
being for Page
pedicle
routine
taken, 12 of V1.0 . 8 26 ®
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 Routine surveillance MRI Breast following bilateral investigational, Surveillance Low Pati MRI coverage and/or Suspicious or guidance
Imaging indeterminate eviCore healthcare Rights . All risk date,To ev policy. Their coverage policies will take precedence over eviCore guidelines. surveillance MRI in these patients would also not be included in the coverage breas Certain payers donot include breast implants in their coverage policies if the A lesion categorized as have BI Repeat ( ents risk, Radiologist Report)inBR-5
Breast
If individuals If 18 stability, mortality. factor
repeat repeat with t implants were placed as part of purely cosmetic surgery. Thus, probably Guidelines or policies months
the (BI
should physical
MRI BR-4: dense is
- i
or dence RADS™ the as imaging imaging breast
However, lesion(s)
iginal
, , take for risk
and there
benign not finding breasts
silent/asymptomatic exam, does nots
profile.
MRI be precedence density type 24
4 4 is remains is
BI-
that used months (BI or
no should certain
such such
study Reserved. as
5)
-
RADS evidence RADS™
Breast can
[Se
determined lesion to : BI-R uggest MRIBreastIndications].
as
(mammogram, assessedbe e heading“EquivocalorOccultFindings” determine from
payers
be - over ™ 1 1 ™ RADS
palpable masses
ADS readily on
3) i the basis
mproved outcomes for w eviCore or
mammogram rupture is lesions may ™ ™ 3,
2, date by
biopsy 4 o
biopsied, NOT that
then
mammogram cover as repeat
r 5should be biopsied. of
guidelines.
US, of
surveillance 8924 8924
benign imaging the mastectomy is not indicated.
silicone recommendations
this
Indicated or
and
initial original
either and/or
MRI) surveillance
(Cat
microcalcifications
13,14,15 reverts
17,18 implants imaging
using
in
ultrasound reduces study 2). 6
w omen 16
months
to
imaging
. .
at
is www.eviCore.com routine After and
for 16 12 morbidity considered Page
hose only suspicious
those months 2 2 years per . 13 3,6 V1.0 45
of
, , 26
of
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 Resi Newl Newl Equivocal P MRI guidelines) breast MRI document equivocal hyllodes
Imaging eviCore healthcare Rights . All with M Evaluate breasts, mammography Evaluate Assessment in A Fat result Discordance Radiologist tissue diagnosis ofmalignantphyllodestumorhaspreviouslybeenestablishedby mastectomy. have close a change observation. conflicting uninterpretable. ultrasound discrete
dual
fter Breast Breast y y 6 6 BreastRI probably
Diagnosed Diagnosed If If May individuals 24 findings surgery finding reconstruction, Necrosis
months
physical the repeat repeat
or
does
Guidelines
months diagnosis. successful successful or or Tumor .
in 26,28 evaluate
is palpable can reconstructed Recurrent
discordant Occult Occult uncertain. clin or
surgical findings should
indicated
(BI i benig
or (lumpectomy
not Repor of con
imaging imaging s
29 ical be of betw (mo examination
preoperatively indicated toestablish (Cystosarcoma
BR-5: positive - fat risk from Breast Paget’s RADS
adequately res and/or firm 1 repeated
Findings 18,19,20 suspicion n st with necrosis mass. een t be
lesion
idual
profile. management lesion free
on
Malignancy Recommendation 5
commonly the
biopsy, breast
for assessed is remains TM
Cancer MRI
mammography margins,
imaging BI-R ultrasound,
breasts, Disease (
4 4
date injection,
breast S tumor MRI
Reserved. sampling or ee PracticeNote) on
at or
or
in of if implant
mastectomy explain
ADS before
least a a
5). MRI of Ultrasound
other BI-R 4 recurrence,
Phyllodes)
in
due (including augmentation, woman findings
the
Breast 5 as and when MRI
.
™ 1 1 ™
(thereafter
29 patients 6 6 and
(MRI
ADS
benign
if if clinical consideration initial to rupture the months
possible those histology Breast
or
trauma capsular for the or
™ with abnormal BI
and 2,
or with ultrasound imaging.
DCIS) MRI
-
who following findings 3,
RADS (Cat
indicators.
then
evaluations Indications a a when
mammogram
after
can treat core repeat
chest
or or
history
Breast breast is
have 8924 8924
contracture 2). .
imaging
1,6,24,25,26 surgery) without be
TM benign
an mammography needle findings as for
16 After may
extent ofdisease where a
3) 3) evaluations
wall used at
surgical undergone MRI of DCIS
of implants and This
should 12 a a
are 2 indicate
breast
recurrences and
reconstruction) reverts
finding biopsy
directed inconclusive for
months, reports years on
according
applies inconclusive to:
further nonspecific, mammogram undergo
management
(saline cancer
a a
with lumpectomy of findings. to that
or inconclusive
significant
breast
18 to www.eviCore.com stability, routine
evaluation ultrasound
is
following
intact to months,
or Page treated repeat
or not
these
or
silicone),
biopsy
Biopsy a
per
14 conflict and/or vs. the V1.0
and
MRI of
with
and
is
26
to
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 MRI MRI MRI with MRI 1 1 10. 6 9 8 7 5 4 3 2. 1. 2 1. Indications ......
breast screening screening screening screening
Imaging eviCore healthcare Rights . All Clinical with A cancer One age One Two indicated relatives First additional The ATM, PTEN age BRCA Patients whichever starting Li BRCAPRO clinical patient
- first Fraumeni
cancer
- 25 50 following breast or first first degree
CHEK2, Guidelines
or Mutation .
1
.
of BARD1, Lobular Atypical Atypical risk unknown
has more
lifetime begins to to to for
at
) )
- - or with . second
degree degree )
with
intermediate
MRI begin begin begin
age comes
,
BRCA annual cancer estimator
been models
but
Syndrome relative first a
have
BRCA
NBN
20
screening at
history
carcinoma risk
lobular ductal (Cowden not MSH2, - at at at
relative relative -
significance, degree tested
age degree first or . 2
age diagnosis age .
unknown , MRI
prior estimated
begin
1 (parent, at
Peutz
such .
40,
hyperplasia
of
penetrance.
the or hyperplasia determined 20: (TP53 MLH1,
B and
male with with to
:
relatives is Syndrome
or BRCA
Reserved.
age reast
- in
as age
High Jehgers the not
10
negative
situ or sibling, but
bilateral breast
Gail, genetic
at relative M mutation)
40
age of indicated years insufficient
screening greater 2,
SH6, not (LCIS)
Risk
the with
(ADH) 41
Claus, if by
(ALH) of
), Syndrome
cancer
prior child patient
for earliest
before
CDH1, variants breast 25 (father, gene
PMS2,
breast Indications
21
should than
: mutation
at
.
to ,42,43 4,12,22,30
Tyrer
Half
evidence
S
this
or mutation
age has
the
cancer,
NF1, or diagnosed ee
EPCAM,
brother, or
ovarian favoring
(STK11
siblings -
start time:
equal Cuzick age ovarian not 25 table 8924 8924
then PALB2 :
been
: annual
of of or
to uncle
cancer
/
below: RAD51C, polymorphism, LKB1 breast annual relative are both (also
cancer breast 20%
tested begin
considered
,
breast
breast
grandfather known
gene
that using
cancer
screening
when . cancer
age
for Genetic
was
screening variations)
and genetic BRCA as
30 first risk
genetic www.eviCore.com diagnosed in second
IBIS)
ovarian )
is
the diagnosed and variants diagnosed Page
. mutation
not risk
or family, MRI
begin
variants
degree
15 or V1.0
≤
of of
26 (If
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Practice Breast ©2020 1 1 1 1 6 5 4 3 MRI State Specific Density Reporting and Imaging Mandate Laws sonographically Phyllodes . . . .
Imaging eviCore healthcare Rights . All phyllodes), If Treatment Diagnosis Phyllodes density Breast It fibroadenoma, imaging, biopsy). shown involving recommended. breast MRI tissue breast MRI breast breast MRI radiotherapy Annual exposure estimated such
should biopsy has Notes
Breast Breast Breast a a as
Guidelines
( Tumor cancer cancer. cancer cancer
densi to Breast DensityBreast Total Total Mini Axilla Mediastinal Whole Chest MRI notification
predilection
the
FNA not
es
which members be
in
at
tum is
is
-
tablishes
it surveillance surveillance surveillance
Gail, mantle, the
Breast
be ty
greater body
(TLI) mad (whichever of suspicious
wid
should (thorax) (Cystosarcoma biopsy (not (not (not 11,12 lung or
notification
although
value following may used
e Claus, is
e
or irradiation
treated treated treated
local is
Personal usually by
laws m in
than
s
for
a a include
be
recommended is ubtotal antle, in
in Category tissue these
diagnosis
inaccurate
(annual) (annual) (annual) Tyrer occurs local
lieu
treated excision. distinguishing
fields findings or vary, they
Reserved. with with with
laws benign or equal
(TBI) of (SLTI) - Additional states,
MRI
diagnosis
Cuzick recurrence
H extended
may bilateral bilateral bilateral
for
but Phyllodes) later) mammographically, D) istory
is is is as have
to
any
(ACR
of
and/or Axillary on
indicated indicated indicated
some a a
and exhibit in lymphoid beginning
20%
their for
or malignant
mammography soft pediatric
phyllodes
been mastectomy) mastectomy) mastectomy)
of
BRCAPRO Practice Practice fibroadenoma
mantle patients has (percutaneous
using
R
also
ultrasound. following B legislative
tissue
lymph isks: rapid
reast
for for for put clinical irradiation
at
contai
cancer: genetic patients patients patients
phyllodes
receiving 8924 8924 age into sarcoma ( sarcoma
tumor growth.
Guidelines). node dissection C
models
diagnosed and who ancer local
.
characteristics clinically, 39 25 n n effect mandates
For
risk
from
mandates
with with with diagnosis
or extremely core a had
excision. Breast therapeutic
(cystosarcoma (cystosarcoma
8 applicable or prior
by
See a a a years phyllodes
clinical
biop personal personal personal
before clinical many and/or
to
should
- ONC MRI
initial for dense after sy and
is
risk of
states. states.
www.eviCore.com
radiation or age additional not
lifetime requests has
12: history history history is tumor. completion
diagnosis
excisional be Page estimator
breast
not necessary. 50
not followed. . 39
Breast risk
16
of of of
been V1.0
of
of
of 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______Breast ©2020
Imaging eviCore healthcare Rights . All Guidelines Sarcomas– Guidelines ). 18,19,20 Bone,
Soft
Reserved. Tissue
and
GIST
in
the 8924 8924
Oncology
Imaging www.eviCore.com
Page 17 V1.0 of 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Pract Breast ©2020 prolactinoma; For and and If unilateral, Mammogram Physiologic Pathologic determined commonly single colors hyperprolactinemia ipple nip
ice Imaging eviCore healthcare Rights . All If If
technically milky the mammogram ple mammogram the
Notes duct, including
patient
discharge n
discharge, Guidelines
limited)
BR-6: - multi nipple
by nipple persistent,
and pituitary results. limited,
can discharge serous, duct.
discharge
and should ultrasound
discharge is an
can be
Nipple prolactin physiologic,
d
It
31,32,33,34 MRI
imaging ultrasound reassured. and
ultrasound
is be yellow,
be is predominantly B
considered spontaneous.
Reserved.
is pathologic, reast obtained is (CPT
and defined
is predominantly green, Discharge/Galactorrhea
not there 31,32,33,34
are can TSH are ® 76641:
needed negative,
as
(S as be negative, brown,
are levels ductography
milky,
ee initial unilateral, performed.
no
unilateral, Practice
if
suspicious suspicious are bilateral, or
imaging,
normal but no
and gray.
8924 8924 recommended
additio may
bloody
31,32,33,34 ductography should Note
complete Evaluation serum
but be with nal findings
). white may or 31,32
be
clinical
imaging
serous, serous, Prolactin.
attempted.
be or 33,34
to or
for is on
CPT
a unilateral. diagnose
pathway unavailable
www.eviCore.com clinical variety is arising
® necessary, Page 76642:
exam,
of
18 from It V1.0
is of or a 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Practice Breast ©2020 The CPT Advanc Mammogram exam, negative pregnancy
Imaging eviCore healthcare Rights . All If
® risk evaluation Notes 76642:
mammogram, ed
of evaluation Guidelines
imaging malignancy test, m
unilateral, and BR-7: is
ammogram ultrasound not
is (evaluation
ultrasound) NOT
negative,
following
limited) Breast
routinely Reserved.
are and . S includes 39 a a
has the ee
ultrasound negative
indicated
BR-5: Pain
initial been
patient imaging estimated MRI clinical
(Mastodynia) (CPT in
Breast patients history 8924 8924
® examination for 76641: to
breast
and
Indications
be with
only
physical unilateral,
breast pain.
(clinical 0.5%.
39
.
pain
exam, www.eviCore.com
39 complete breast Page and 19 V1.0
of or 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast Practice ©2020 While New investigational Positron EmissionMammography
Imaging eviCore healthcare Rights . All Impedance Thermography PET Nuclear time fo There Cone CT transmission, Other BR-8:
and/or r
Notes alternative
this modality, and this procedure should be considered investigational at this showed that PEM and MRI hadcomparable breast mammography. The radiation exposure from a PEM study is 23 times higher than for digital levels. need for MRI hadgreater lesion women underwent both high- breastcancer ant A prospective multi modalities well as in detecting incidental breast cancers not seen on other imaging identified as suspicious onconventional imaging or physical examination, as Early clinical trials have shown high clinical accuracy in characterizing lesions technique is especially adept at detecting ductal carcinoma in situ. and allows visualization of intraductal as well as invasive breast cancers. This The spatial resolution of this technique is at the individual duct level (1.5 mm) breast Requesting providers often ask for PEM as CPT mammogram. allowing The PEM high Systems, also referred to as Naviscan™ or PET mammography, performs High Molecular Scint Breast Breast
Mammography
Beam techniques Guidelines is currently insufficient data available to generate appropriateness criteria -
-
imammography breas resolution positron- alternative
resolution ”.
Of Of these, 3.6% of the women had tumors seen only with PEM. specific Alternative
with
Ma
acquisition of the emission images immediately after mastectomy. PEM had greater specificity at the breast and lesion CT
detectors are integrated into a conventional mammography system,
breast breast nitrous t
mmography
imaging,
respect B
reast to
gamma metabolic imaging for breast cancer using anFDG tracer.
breast
de (P
imaging imaging i oxide cipating breast -
tect EM) center clinical trial for women with newly diagnosed
to including: Reserved.
-
both imaging
imaging level sensitivity andmore accurately depicted the oxygen production emission mammography (PEM) by Naviscan™ PET
Breast (MBI) techniques screening resolutionPEM imagi
consumption, techniques (BSGI) - conservation surgerywas performed. These
Imaging may
and
have
8924 8924 diagnosis include:
light FDA ® 78811 or “PET scan of the
ng and breast MRI. Results absorption, - Approaches level sensitivity, although
approval, of
breast
the
microwave www.eviCore.com
cancer. they Page
remain
20
V1.0 of
26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 Breast recommended For discharge. For inconclusive physical There ultrasound Further requires
Imaging eviCore healthcare Rights . All
men men
is cancer diagnostic BR-9:
tissue tissue
examination, limited <25 ≥ Guidelines 25 if
or mammography years years
in suspicious. as
diagnosis. evidence
men
Suspected initial
pathway
of of
presents age age mammography imaging on
with with
for
Reserved.
is the
inconclusive suspicious an an as
followed use a mass, a mass, indeterminate indeterminate
Breast
of
is
MRI
recommended by
clinical skin/nipple
or in mammography suspicious.
the
Cancer palpable mass palpable or
8924 8924 evaluation
imaging
change,
initially mass,
in if
findings
of
ultrasound
followed or
male or
Males ultrasound
pathologic
with
www.eviCore.com usually breast a a
by Page concerning is
is
disease. nipple 21 V1.0 of 26
Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Breast ©2020 BR-10: Breast mammogram bloody If IV contraindicated recommended pregnant/lactating
Imaging eviCore healthcare Rights . All Gadolinium
US nipple Guidelines
is Evaluation
first
discharge (with
is after in
- required line
pregnancy.
lead
mammogram woman
imaging
abdominal and with
Reserved.
has US
in
Biopsy, in MRI
a is pregnant Pregnant and
palpable
negative
shielding). to
evaluate rather US.
and mass mass or
than suspicious, suspicious,
lactating breast
or OR advanced 8924 8924
Lactating has parenchyma,
women.
persistent follow imaging,
with
but
unilateral
www.eviCore.com is diagnostic Women
is Page 22 V1.0 of
26
Breast Imaging 11. CD, Lehman 10. .Dorrius 9. of College American 14. Mendelson 4. 8. 3 Emaus 13. 18. BL, Sprague 3. 7 McCarthy 17. 16. .National 5. 12. 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______15. MB, Mainiero 2. 1. Reference Breast .Moy 7. .Peters 6. ©2020 Guidelines™) Cancer. Testing. NCCN 2013 detection systematic trial review ultra detection Reconstructive - Pinel 1134. Holmich screening findin rights MRI based Gynecologists. Oncology Thyroid br NCCN. the may herein complete for atlas Ann https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/bre November Final Sickles - Dense - Publications/Committee by diagnosed ast Breast screening NCCN.org. Cancer Comprehensive Saslow Siu east
- Imaging
any eviCore healthcare Rights . All cancer AL.
study
sonography Intern as , L, ;
gs
Recommendation Giroux breast reserved. – 200(6):W683
practice
lesions.
Guidelines of
G, NHG,
system data and reporting imaging
Breasts
Elias
purpose MJ, an ? EA
MD, D, for Screening
Carcinoma. L
Referenced National Cancer Comprehensive
s s
surgical
Journal American
novice among of
of version . R, (NCCN
n. n. desig
CM, for
-
Boetes adjunct
Journal Med. 2016.
review
. screening D’Orsi and To EB,
Guidelines not Bakker V
breast
I, Vejborg reporting imaging K, FM,
Stout
Blume
Borel
rupture: A, Lourenco mammography an der
for
view
- Pusi
Radiology
to approach Obstet
Surgery in be reproduced Pate - Diagnosed Böhm
The
without 2016 screening
Breast C Comprehensive El
a
methods Guidelines™) Radiology
Version NK, NK,
C,
to
of cancer Rinkes
c c
MF, nd
most the Khoury the JD,
Referenced l . W689
NCCN
with Obstetricians
MC Weide A, mammography Burke
V, the ; - breast
do U.S.
Vélez Gynecol CJ. - meta - 164(4):279 Conrad
: Schechter
Statement: NCCN Kerrigan and
Peeters the et DeMartini Network, breast experienced and - Opinions/Committee Cancer July
American permission ; 2008
in
ACR 2.2017. Mahoney al. IH for
e
by and spectrum
W, of patient Guidelines™ MM,
.
analysis
M, cancer: 50 aged women
M, xpress . recent ; 1 ; 2004 2015
-
Is
food Roentgenology . Mammography#here Opinion Committee with women C,
. and Guidelines, et
J, J,
Berg BI Breast 246(1). Zuithoff ; 2015
for PHM,
2.2017 with Trop any
Network
Reserved. al. Inc.
Ooijen van
et -
C, ; WB,
296. Gynecologists. and
Invasive
RADS
ca and system data Breast College
ancer Breast 277(2).
complete and
. written
al MC,
.
Cancer American 14 US from et from permission WA, form
CL.
CA re? Eur
All I, . . 125
et
MRI (1): et Untreated al. drug
© et NP
Preventive
® National 2014 al. rights
Cancer et and
Plastic
Silicone of
. Network
al.
Radiol. NCCN the
(NCCN) et
Cancer: for al. Benefits - 204 Cancer Follow breastsdense go Reston,
https://www.acog.org/Resources A,
permission of Breast al.
helpful
findings imaging MR
recommendations administration al.
Accuracy
-
PM . medical Continuing
on- illustrations 75 any
to online Radiology et
; 1 ; 2009
ACR
214 reserved. .
ACR
& & as Imaging MRI J J al. College American Gynecologic A, years
-
August
purpose breast
Silicone
up
of version No.
Screening (NCCN)
, Guidelines Cancer: Reconstructive . Clin . . Screening
in
VA, et - Meta Services harms, Appropriateness
Clinical
BI
and Outcome readers
evaluationthe
the
al.
93(4) 625
Management
Society and
with
of - NCCN.org ; 2007 of College American Cancer Comprehensive RADS .
implants
Computer . The ; 2011 analysis ; 2013 NCCN may herein NCCN. the
Ann Breast
American without
interpretation
Guidelines Principles : and cost 8924 8924 extremely an
- 986 .
the Practice . Task - d and
Radiographics 57(2) NCCN Practice/Management Version G ® Journal American
U.S.
Intern additional
– 21(8):1600 - 10(1):11 Ultrasound. NCCN uidelines . 993 Clinical
education:
. Implant
Diagnosis
magnetic and
of Surgery: the
Force - - :75 of Services Task Preventive Monitoring.
Aided -
of of
MR
eproduced
effectiveness College
Guidelines™
To
Criteria not
Med Guidelines
Radiology of
breasts dense
– – 2.2017 express 2.2017: Version with women mammographic inconclusive
89. Guidelines,
Breast Dedicated view
Practice
imaging 14. time statement. recommendation be
screening
. Rupture, for in Detection
; ; 2015
April
1608.
- . ACR In: r 2.2017. breast Radiology ®
And
of
2013
breast the
of reflect
Breast
written
In:
May . Obstetricians of of
Network,
resonance
computer 2008 -
in . 2013 most - 162(3):157 in Guidelines
; ACR
illustrations and of
www.eviCore.com
Roentgenology Plastic
Oncology breasts dense reconstruction: go 33(2):
modality the
-
screening : ©
17, BI an of
supplemental cancer The 2017 ;
of permission
. - to online Page Breast - recent
(4 121 Breast
Women RADS di
BI - evidence 2013. in 2017.
agnosis 435-
Inc. & - - DENSE
MRI aided RADS
any National imaging
23 in ): for
. 166
(NCCN and Force and ® All MRI V1.0 453. - 1127
with
form -
Atlas, of With the ®
of : A : 26 . -
Breast Imaging 21. 28. 30. 20. 27. 26. 22. 25. 23. 29. 24. 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______19. Breast ©2020
Clinical (NCCN) NCCN 2012 Clinical NCCN (NCCN) recently for andsurveillance workup of RADS online Tan CD, Lehman NCCN Guidelines, written NCCN Institute Network NCCN Network NCCN p illustrations pathologic online of permission illustrations NCCN the Gu (NCCN) written written and and and NCCN Morris Guidelines, Moy National Lim National © © © Institute Radiology Grau 2014 2014 2014 ermission
the idelines, Imaging eviCore healthcare Rights . All
HS illustrations illustrations illustrations H, L, ; AM
81(1) College American
® to
to
National National National
Z EA, Guidelines Guidelines Guidelines Clinical Clinical Guidelines Guidelines of permission of permission permission
N
Practice Practice
Atlas,
et
breast diagnosed
for
for Guidelines Guidelines Guidelines S, hang Cancer Comprehensive Cancer Comprehensive (NCCN) (NCCN) ewell , NCCN.org. NCCN.org
.
Bapsi
al. correlation. Clinical
Comstock
2013. : of Guidelines Clinical Clinical go herein herein go go e62-
Gatsonis
Paget
NCCN. the NCCN. the
Breast
o
M
online Practice online Practice Comprehensive Comprehensive Comprehensive
nline herein herein herein
C, Guideli Guidelines . 69. S,
Liu Guidelines Guidelines
Version Version Version Version Version may may Practice
CCN.
of
Mahoney Chugh . . Systems Improvement Systems Version Version Version of Disease
H,
to
the the t Reporting Imaging to to CE, he
Radiographics C,
may may may
nes et not not Guidelines Guidelines
NCCN.org NCCN.org. NCCN.org of
NCCN. NCCN. N
To To
Kuhl
R, al, Lee CH, cancer.
2.2017: 2.2017: 2.2017: 1.1017: 2.2017:
Radiology
be reproduced be reproduced n
Guidelines in in local not not 2.2017: 2.2017:
2.2017:
Version Version view view Improvement findings Imaging ot MC, et
Oncology Oncology
CK,
the
in be reproduced in be reproduced in be reproduced Cancer Cancer Cancer al.
To To To Network, Network, recurrence
Reserved. N most the most the et
. . . . Invasive Ductal Phyllodes Paget’s Breast et in in breast: Phyllodes et
view view view Breast Breast Breast
al. Engl
2.2017: 2.2017: . . Oncology Oncology al. al.
; 2011 ; ; 2016 in
ACR
Network, Network, Network
and (NCCN (NCCN ACR
MRI J J most the Oncology most the most the
in Carcinoma Cancer
in in mammographic,
(ICSI) Diagnosis (ICSI). Inc. Inc.
Disease. recent recent Cancer. Cancer. Cancer. . Med Breast
31(7) 13(11):43 and System. Data
Appropriateness any any Breast Breast Tumor
evaluation tumors
BI in
All All (NCCN (NCCN
- , Guidelines™) Guidelines™) phyllodes
;
RADS
distant form form 2007
any any any Inc. Inc. Inc.
r
; Jan. 2012 Risk
and rights and
recent recent recent
ights Cancer - 1973
(NCCN
Referenced Referenced Breast Cancer. Cancer. National National
of
form form form All All All
- for for complete complete ; March
Reduction
® 52.
Guidelines™) Guidelines™) breast. the
Situ.
reserved. reserved. metastases of
Magnetic rights rights rights 1987.
complete and complete and complete and any any
tumor for for for
National contralateral the Reston, Cancer. Guidelines™) US, 8924 8924
45 p. of
Referenced Referenced National
Comprehensive Comprehensive
purpose purpose
criteria any any any
- 356(13):1295
for for breast reserved. reserved. reserved.
and of version of version with with s s
National Breast Breast
purpose purpose purpose The The of Imaging. Resonance
UpToDate,
VA, Referenced C Comprehensive
MR
in
breast. the permission permission
sta for for disease. Cancer Comprehensive
without without NCCN NCCN asymptomatic
version version version American
findings imaging
ge
east
The The The Cancer Cancer Breast Breast with with
f
or Cancer Comprehensive the the I
without without without breast
1303. breast Br
NCCN NCCN NCCN
Cancer Cancer
from permission from permission Guidelines™ Guidelines™
. . 6/2017 the the NCCN NCCN (MN): Bloomington
of of of
with Eur Cancer Cancer
from from 2.2017 2.2017
of College
NCCN the NCCN the NCCN the
express express
in www.eviCore.com the the the
J J cancer:
Cancer
from permission Guidelines™ Guidelines™ Guidelines™
with women
wo Guidelines, Guidelines, Network Network NCCN the NCCN the ancer Radiol express express express Page
In: 2.2017 2.2017 men. © ©
with 2014 2014
written written
ACR
and and initial 2.2017
Network . 24
Jan
Journal V1.0
the the of
BI
go go
26
-
Breast Imaging 39. 35. 38. 34. 47. 36. 43. 41. 33. 46. 40. 44. 32. 37. 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______45. 42. 31. Breast ©2020
S
Expert Radiol. ultrasound, - 209(6):1404 the for Morrogh doi:10.2214/ajr.18.20157. Lee CH, Bahl Roentgenolog Discordant Imaging Europe. 2019;35(5). 13- 2019;35(5). Europe. Imaging Journal pathologic Referenced of College Expert resonance Guidelines™) National NCCN Guidelines, express Centers Women Berger Treatment. Guidelines™ https://www.cdc.gov/genomics/gtesting/file/print/fbr/BCAnaVal.pdf complete for complete for rights rights Discharge. Sanders bilateral Monticciolo Koning Lee 3.2018 from Screening. Berg of Cancer Referenced Golan NCCN NCCN Guidelines™) National anders LM. Breast MRI in the management of the discordant the of management the in MRI Breast LM. anders
Radiolo
Imaging evaluation the any any eviCore healthcare Rights . All Society SJ,
M, NCCN the WA
reserved. reserved.
O,
Jokich Im, MB, Mainiero Im, Guidelines Guidelines Guidelines
N, purpose purpose © ; 7 ; 2010
Breast
Network
of MA, Gadd
Trikha
at for mastectomy written 2018 Dershaw Cancer Comprehensive Cancer Comprehensive M, LM,
.
Amitai versio of version
gy.
Luparia
Current Nuclear
Radiology
nipple Higher
imaging
Core Journal CollegeAmerican
- 2018;174(2):463 Guidelines other and of Disease go DL, Morris with with
1410.
El and
2014(5S). y.
National for for Breast
CT. online - (1):18
S,
-
permission n Newell Clinical The The Madany
without without August Y, (NCCN) Bio
from permission
from permission
discharge: Breast - Breast of
of illustrations Moy PM,
- Than
DD, Version status
L, berman Version Version A,
Medicine CD. Lehman E Koning Barnea of
in
psy the the pathologic Control
A, NCCN NCCN
.
Di
and the and Imaging
to 27
technologies the - 2018;15(3):408 the
Bailey
L, Kopans Cancer Comprehensive
Li
MS,
NCCN NCCN G, Practice
; 2017 the the NCCN.org.
Risk: Average . . Results.
Cancer
Cancer Moy M,
of et Guidelines
American reconstruction: management
3.
9, 3.201 Corporation. 3.2018, et
Y, of
dedicated
al express express Guidelines™ Guidelines™ . a Persing Moy (CDC). Prevention and Feb 2016 . 2019
468.
h
L,
al. . L, of NCCN. the Menes - 209(2):465 systematic
ACR may erein Guidelines, Guidelines,
D, nipple
et
3.
et Diagnostic
Radiology
Diagnostic 16. 3.2019
Guidelines L,
Journal American
Network Network
NCCN the Reserved. NCCN the
- doi:10.1007/s10549
et
al. 2019
al.
Genetic/Familial Genetic/Familial Breast for
Niell
College et
Appropriateness A, written written al.
Version
ACR TS.
ACR
. discharge nuclear ; . . 414 ACR
al. the Recommendations
Mehta
57(Supplement Breast of http://koninghealth.com/en/kbct/.
© © B, a
National 2019 National 2019 To The and and
Yield
not review 471. Cancer
. discharge nipple (NCCN) (NCCN) detection
.
Appropriateness u cohort retrospective
go go Appropriateness Monsees
permission permission use on the of Performance - 14(11s):s383
in
of
Clinical Clinical view tility
3.2018:
be reproduced
illustrations illustrations A. predictive
breast
to online to online Oncology
Radiology cancer
of Network,
Use and American
of
magnetic surveillance the Screening
Guidelines Guidelines
of
High - High MRI of
Practice Practice
imaging. B,
Breast Criteria of - meta
most Roentgenology.
screening 018-
clinically
of
of of
1):46S NCCN.org. NCCN.org Sickles Cancer Comprehensive Cancer Comprehensive Contrast
value
after (NCCN
. Ri
Inc.
Risk mammography, s390.
may herein may herein NCCN. the NCCN. the ; 2017 From
-9. -9. 05077
sk recent analysis
Journal
8924 8924 MRI
Criteria Ann Criteria Cancer. ®
in
and
Guidelines Guidelines All
negative - - Assessment: Society Version Version Assessment: of Evaluation
core benign 52S.
any
study. EA. occult
14 ACR.the - rights Guidelines™) Oncol Surg versus
with ductography Enhanced Diagnosis.
. . . complete and
(5): ®
. form of
® Breast
AJR.
Breast
Referenced
Breast imaging: To To
not not
Roentgenology
3.
of - 138 Breast breast
- 2019;212(5):1157 3.2019: reserved. or
imaging resonance : 2019
for in view view in breast
Accessed
be reproduced be reproduced
of
mammography inconclusive breast Journal Journal American
153. Oncology Oncology
Cancer
biopsy. Diagnostic Diagnostic biopsy.
Breast
any
Breast . MRI Nipple Pain. National Cancer
2007
cancer.
Cancer the the
and
recommendations Breast Breast for
imaging
purpose
Network, Network, version MRI, The in
with
most most
College American ; of Breast
magnetic
and and Ovarian. www.eviCore.com Screening Management 14; March
J J the
. (NCCN (NCCN
NCCN
and Research Comprehensive
Cancer. Cancer permission breast
; 2017
in Page Am recent recent 3369 . . Ovarian
of white
American in in
without 1165. women
Cancer Inc. Inc.
18,
the any any Coll
after . .
of 25 .
in and and All All r. r. pape 2019.
V1.0 NCCN
form form
of
the
with of from 26
Breast Imaging 50. 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______49. 48. Breast ©2020
. . doi:10.1016/j.jacr.2018.09.013 2018;15(11). Radiology. of College American the of Journal Women. Lactating and Pregnant B (MRI) the of P http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf 2018. October pg 90. Group; Oncology Children’s CA: Monrovia, 5.0. version cancers, adult young - Long Group. Oncology Children’s Diflorio ACR P arameters/mr
Imaging eviCore healthcare Rights . All ractice ractice - Alexander RM, Slanetz PJ, Moy L, et al. ACR Appropriateness Criteria Moy Appropriateness al. et ACR L, PJ, Slanetz RM, Alexander Guidelines reast. Revised 2018. (Resolution 34). https://www.acr.org/ 34). (Resolution 2018. Revised reast. P - arameter contrast
- breast.pdf
P the for Reserved. erformance of erformance term follow up guidelines for survivors of childhood, adolescent and and adolescent childhood, of survivors for guidelines up follow term .
C ontrast - Enhanced Enhanced 8924 8924 M agnetic - - /media/ACR/Files/Practice
R ® . .
Breast Imaging of of Imaging Breast I esonance www.eviCore.com Page maging 26 V1.0 of 26
Breast Imaging